Brief: Sandoz Launches Denosumab Biosimilars In Europe

Sandoz AG

01/12/2025 06:03

Dec 1 (Reuters) - SANDOZ GROUP AG SDZ.S:

LAUNCHES DENOSUMAB BIOSIMILARS IN EUROPE, PROVIDING AFFORDABLE TREATMENT OPTION FOR CANCER-RELATED BONE DISEASE AND OSTEOPOROSIS FOR MILLIONS OF PATIENTS

WYOST (DENOSUMAB 120 MG) / JUBBONTI (DENOSUMAB 60 MG) APPROVED TO TREAT CANCER-RELATED BONE DISEASE / OSTEOPOROSIS ACROSS ALL INDICATIONS OF REFERENCE MEDICINES

Source text: ID:nEQ9RGDB3a

Further company coverage: SDZ.S

 (Gdansk Newsroom)

 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))